eculizumab gMG
Selected indexed studies
- Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. (Muscle Nerve, 2019) [PMID:30767274]
- Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. (Pediatr Neurol, 2024) [PMID:38810600]
- Myasthenia gravis: the role of complement at the neuromuscular junction. (Ann N Y Acad Sci, 2018) [PMID:29266249]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. (2019) pubmed
- Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. (2024) pubmed
- Myasthenia gravis: the role of complement at the neuromuscular junction. (2018) pubmed
- A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. (2024) pubmed
- Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study. (2024) pubmed
- Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. (2024) pubmed
- The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis. (2024) pubmed
- Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. (2021) pubmed
- Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. (2025) pubmed
- Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis. (2024) pubmed